ERYTECH Pharma S.A. (ERYP) Stock Analysis

What ERYTECH Pharma S.A. does

ERYTECH Pharma S.A. is a biopharmaceutical company specializing in the clinical development of red blood cell-based treatments for various cancers and orphan diseases. Its operations are based in France and the United States. The company's most advanced investigational therapy, eryaspase, is currently undergoing Phase 3 clinical trials for second-line pancreatic cancer, and Phase 2 studies for patients with triple-negative breast cancer and second-line acute lymphoblastic leukemia. Furthermore, ERYTECH is developing erymethionase, a preclinical candidate that employs methionine-γ-lyase encapsulated in red blood cells to target methionine-dependent tumors. Founded in 2004, the firm's headquarters are located in Lyon, France.

Key metrics

ETFs linked to ERYP

Broad-market and Healthcare sector ETFs an investor holding ERYTECH Pharma S.A. is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ERYP fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for ERYTECH Pharma S.A.?

ERYTECH Pharma S.A. trades under the ticker ERYP on NASDAQ.

Which exchange is ERYP listed on?

ERYP is listed on NASDAQ.

What sector does ERYTECH Pharma S.A. operate in?

ERYTECH Pharma S.A. is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ERYP in a portfolio?

PortView shows ERYP's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.